| Line Item | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|
| Operating expenses: | |||||||||
| Selling, General and Administrative Expense | |||||||||
| Research and Development Expense | — | — | — | ||||||
| Total operating expenses | |||||||||
| Loss from operations | |||||||||
| Other income (expenses): | |||||||||
| Net Interest Income | |||||||||
| Amortization of debt discount | — | — | — | ||||||
| Foreign Currency Gain/Loss | — | ||||||||
| Gain on fair value adjustments of warrant | |||||||||
| Loss on fair value adjustments of derivative | — | — | — | ||||||
| Non-Operating Income (Expense) | — | ||||||||
| Restructuring Expense | — | — | — | ||||||
| Total other income | |||||||||
| Income Before Tax | |||||||||
| Income tax expense | — | — | — | — | |||||
| Net income (loss) from continuing operations | |||||||||
| Net Income (Loss) |